open access
Standard therapy or additionally radioactive iodine (131I) therapy; which will stop the recurrence of glioblastoma multiforme (GBM)?
, 2, 3, 2, 2, 4, 4, 4, 5, 5, 6, 1, 78, 9, 2, 2, 10
Affiliations- Department of Pharmacology, Poznan University of Medical Sciences, Poznan, Poland
- Department of Endocrinology, Metabolism, and Internal Medicine, Poznan University of Medical Sciences, Poznan, Poland
- Department of Paediatric Endocrinology and Rheumatology, Institute of Paediatrics, Poznan University of Medical Sciences, Poznan, Poland
- Department of Radiology, Poznan University of Medical Sciences, Poznan, Poland
- Department of Neurosurgery, Poznan University of Medical Sciences, Poznan, Poland
- Voivodal Specialistic Hospital in Olsztyn, Olsztyn, Poland
- Chair and Department of Medical Genetics, Poznan University of Medical Sciences, Poznan, Poland
- Centres for Medical Genetics GENESIS, Poznan, Poland
- Laboratory of Environmental Research, Department of Toxicology, Poznan University of Medical Sciences, Poznan, Poland
- Coordinator of the International Head and Neck Scientific Group, Padua, Italy
open access
Abstract
Glioblastoma multiforme (GBM) is the most aggressive malignant brain tumour. The average survival time for a patient diagnosed with GBM, using standard treatment methods, is several months. Authors of the article pose a direct question: Is it possible to treat GBM solely with radioactive iodine (131I) therapy without employing the sodium iodide symporter (NIS) gene? After all, NIS has been detected not only in the thyroid but also in various tumours. The main author of this article (A.C.), with the assistance of her colleagues (physicians and pharmacologists), underwent 131I therapy after prior iodine inhibition, resulting in approximately 30% reduction in tumour size as revealed by magnetic resonance imaging (MRI).
Classical therapy for GBM encompasses neurosurgery, conventional radiotherapy, and chemotherapy (e.g. temozolomide). Currently, tyrosine kinase inhibitors (imatinib, sunitinib, and sorafenib) are being used. Additionally, novel drugs such as crizotinib, entrectinib, or larotrectinib are being applied. Recently, personalised multimodal immunotherapy (IMI) based on anti-tumour vaccines derived from oncolytic viruses has been developed, concomitant with the advancement of cellular and molecular immunology. Thus, 131I therapy has been successfully employed for the first time in the case of GBM recurrence.
Abstract
Glioblastoma multiforme (GBM) is the most aggressive malignant brain tumour. The average survival time for a patient diagnosed with GBM, using standard treatment methods, is several months. Authors of the article pose a direct question: Is it possible to treat GBM solely with radioactive iodine (131I) therapy without employing the sodium iodide symporter (NIS) gene? After all, NIS has been detected not only in the thyroid but also in various tumours. The main author of this article (A.C.), with the assistance of her colleagues (physicians and pharmacologists), underwent 131I therapy after prior iodine inhibition, resulting in approximately 30% reduction in tumour size as revealed by magnetic resonance imaging (MRI).
Classical therapy for GBM encompasses neurosurgery, conventional radiotherapy, and chemotherapy (e.g. temozolomide). Currently, tyrosine kinase inhibitors (imatinib, sunitinib, and sorafenib) are being used. Additionally, novel drugs such as crizotinib, entrectinib, or larotrectinib are being applied. Recently, personalised multimodal immunotherapy (IMI) based on anti-tumour vaccines derived from oncolytic viruses has been developed, concomitant with the advancement of cellular and molecular immunology. Thus, 131I therapy has been successfully employed for the first time in the case of GBM recurrence.
Keywords
glioblastoma multiforme (GBM); immunotherapy; chemotherapy; virotherapy; radioactive iodine (131I) therapy; sodium iodide symporter (NIS); gene mutation; cell-free DNA (cfDNA); cancer vaccines; oncolytic viruses
About this articleTitle
Standard therapy or additionally radioactive iodine (131I) therapy; which will stop the recurrence of glioblastoma multiforme (GBM)?
Journal
Issue
Article type
Review paper
Pages
130-139
Published online
2024-03-19
Page views
165
Article views/downloads
23
DOI
Pubmed
Bibliographic record
Endokrynol Pol 2024;75(2):130-139.
Keywords
glioblastoma multiforme (GBM)
immunotherapy
chemotherapy
virotherapy
radioactive iodine (131I) therapy
sodium iodide symporter (NIS)
gene mutation
cell-free DNA (cfDNA)
cancer vaccines
oncolytic viruses
Authors
Agata Czarnywojtek
Paweł Gut
Kamil Dyrka
Jerzy Sowiński
Nadia Sawicka-Gutaj
Katarzyna Katulska
Piotr Stajgis
Mateusz Wykrętowicz
Jakub Moskal
Jeremi Kościński
Krzysztof Pietrończyk
Patryk Graczyk
Maciej Robert Krawczyński
Ewa Florek
Ewelina Szczepanek-Parulska
Marek Ruchała
Alfio Ferlito
References (92)- Schirrmacher V. Cancer Vaccines and Oncolytic Viruses Exert Profoundly Lower Side Effects in Cancer Patients than Other Systemic Therapies: A Comparative Analysis. Biomedicines. 2020; 8(3).
- Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res. 1970; 13: 1–27.
- Gubin MM, Artyomov MN, Mardis ER, et al. Tumor neoantigens: building a framework for personalized cancer immunotherapy. J Clin Invest. 2015; 125(9): 3413–3421.
- Abbas AK, Lichtman AH, Pillai S. Cellular and Molecular Immunology, 9th ed. Elsevier, Amsterdam 2018: 10–550.
- Schirrmacher V. Shifts in tumor cell phenotypes induced by signals from the microenvironment. Relevance for the immunobiology of cancer metastasis. Immunobiology. 1980; 157(2): 89–98.
- Langley RR, Fidler IJ. The seed and soil hypothesis revisited--the role of tumor-stroma interactions in metastasis to different organs. Int J Cancer. 2011; 128(11): 2527–2535.
- Yefenof E. Foreword. In: Yefenof E. ed. Innate and Adaptive Immunity in the Tumor Microenvironment. Springer, New York, NY 2008: v–viii.
- Schirrmacher V, Lorenzen D, Van Gool SW. A New Strategy of Cancer Immunotherapy Combining Hyperthermia/Oncolytic Virus Pretreatment with Specific Autologous Anti-Tumor Vaccination – A Review. Austin Oncol Case Rep. 2017; 2(1).
- Lichterman B. Emergence and early development of Russian neurosurgery (1890s-1930s). J Hist Neurosci. 2007; 16(1-2): 123–137.
- Bennett H, Godlee RJ. Excision of a tumour from the brain. Lancet. 1884; 2: 1090–1091.
- Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001; 95(2): 190–198.
- Hefti M, von Campe G, Moschopulos M, et al. 5-aminolevulinic acid induced protoporphyrin IX fluorescence in high-grade glioma surgery: a one-year experience at a single institutuion. Swiss Med Wkly. 2008; 138(11-12): 180–185.
- McGirt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J Neurosurg. 2009; 110(1): 156–162.
- Regula J, MacRobert AJ, Gorchein A, et al. Photosensitisation and photodynamic therapy of oesophageal, duodenal, and colorectal tumours using 5 aminolaevulinic acid induced protoporphyrin IX 7 - a pilot study. Gut. 1995; 36(1): 67–75.
- Roberts DW, Valdés PA, Harris BT, et al. Glioblastoma multiforme treatment with clinical trials for surgical resection (aminolevulinic acid). Neurosurg Clin N Am. 2012; 23(3): 371–377.
- Stummer W, Stepp H, Möller G, et al. Technical principles for protoporphyrin-IX-fluorescence guided microsurgical resection of malignant glioma tissue. Acta Neurochir (Wien). 1998; 140(10): 995–1000.
- Duffner F, Ritz R, Freudenstein D, et al. Specific intensity imaging for glioblastoma and neural cell cultures with 5-aminolevulinic acid-derived protoporphyrin IX. J Neurooncol. 2005; 71(2): 107–111.
- Parvez K, Parvez A, Zadeh G. The diagnosis and treatment of pseudoprogression, radiation necrosis and brain tumor recurrence. Int J Mol Sci. 2014; 15(7): 11832–11846.
- Ellingson BM, Chung C, Pope WB, et al. Pseudoprogression, radionecrosis, inflammation or true tumor progression? challenges associated with glioblastoma response assessment in an evolving therapeutic landscape. J Neurooncol. 2017; 134(3): 495–504.
- Fraass BA, Kessler ML, McShan DL, et al. Optimization and clinical use of multisegment intensity-modulated radiation therapy for high-dose conformal therapy. Semin Radiat Oncol. 1999; 9(1): 60–77.
- Fiorentini G, Szasz A. Hyperthermia today: electric energy, a new opportunity in cancer treatment. J Cancer Res Ther. 2006; 2(2): 41–46.
- Szigeti G, Szasz O, Hegyi G. Personalised Dosing of Hyperthermia. J Cancer Diagn. 2016; 01(02).
- Szasz O, Szigeti G, Szasz A. Connections between the Specific Absorption Rate and the Local Temperature. Open J Biophys. 2016; 06(03): 53–74.
- Vincze G, Szasz O, Szasz A. Generalization of the Thermal Dose of Hyperthermia in Oncology. Open J Biophys. 2015; 05(04): 97–114.
- Andocs G, Szasz O, Szasz A. Oncothermia treatment of cancer: from the laboratory to clinic. Electromagn Biol Med. 2009; 28(2): 148–165.
- van Rhoon GC. Is CEM43 still a relevant thermal dose parameter for hyperthermia treatment monitoring? Int J Hyperthermia. 2016; 32(1): 50–62.
- White BD, Duan C, Townley HE. Nanoparticle Activation Methods in Cancer Treatment. Biomolecules. 2019; 9(5).
- Czarnywojtek A, Borowska M, Dyrka K, et al. Glioblastoma Multiforme: The Latest Diagnostics and Treatment Techniques. Pharmacology. 2023; 108(5): 423–431.
- Verma J, Lal S, Van Noorden CJF. Nanoparticles for hyperthermic therapy: synthesis strategies and applications in glioblastoma. Int J Nanomedicine. 2014; 9: 2863–2877.
- Attaluri A, Kandala SK, Wabler M, et al. Magnetic nanoparticle hyperthermia enhances radiation therapy: A study in mouse models of human prostate cancer. Int J Hyperthermia. 2015; 31(4): 359–374.
- Gunderson L, Tepper J. Clinical radiation oncology. 4th ed. Elsevier, Amsterdam 2016: 1577–1622.
- Jones EL, Oleson JR, Prosnitz LR, et al. Randomized trial of hyperthermia and radiation for superficial tumors. J Clin Oncol. 2005; 23(13): 3079–3085.
- Wang J. Simulation of magnetic nanoparticle hyperthermia in prostate tumors. Baltimore, Maryland 2014: 1–35.
- Alifieris C, Trafalis DT. Glioblastoma multiforme: Pathogenesis and treatment. Pharmacol Ther. 2015; 152: 63–82.
- Highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761115s000lbl.pdf (01.09.2023).
- Technical Manual, TED 1-0.15A. Section VI: Chapter 2. Controlling Occupational Exposure to Hazardous Drugs. OSHA 1999.
- Stupp R, Mason WP, van den Bent MJ, et al. European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352(10): 987–996.
- Ljubimova JY, Sun T, Mashouf L, et al. Covalent nano delivery systems for selective imaging and treatment of brain tumors. Adv Drug Deliv Rev. 2017; 113: 177–200.
- Mutter N, Stupp R. Temozolomide: a milestone in neuro-oncology and beyond? Expert Rev Anticancer Ther. 2006; 6(8): 1187–1204.
- Highlights of prescribing: TEMODAR® (temozolomide). https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021029s031lbl.pdf (01.09.2023).
- Scaringi C, De Sanctis V, Minniti G, et al. Temozolomide-related hematologic toxicity. Onkologie. 2013; 36(7-8): 444–449.
- Yasaswi PS, Shetty K, Yadav KS. Temozolomide nano enabled medicine: promises made by the nanocarriers in glioblastoma therapy. J Control Release. 2021; 336: 549–571.
- Baxi S, Yang A, Gennarelli RL, et al. Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. BMJ. 2018; 360: k793.
- Reardon DA, Kim TM, Frenel JS, et al. Treatment with pembrolizumab in programmed death ligand 1-positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE-028 trial. Cancer. 2021; 127(10): 1620–1629.
- Aurisicchio L, Pallocca M, Ciliberto G, et al. The perfect personalized cancer therapy: cancer vaccines against neoantigens. J Exp Clin Cancer Res. 2018; 37(1): 86.
- Palande V, Siegal T, Detroja R, et al. Detection of gene mutations and gene-gene fusions in circulating cell-free DNA of glioblastoma patients: an avenue for clinically relevant diagnostic analysis. Mol Oncol. 2022; 16(10): 2098–2114.
- Gleevec (imatinib mesylate) tablet. Daily Med; U.S. National Library of Medicine.
- Sun Li, Liang C, Shirazian S, et al. Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2003; 46(7): 1116–1119.
- Strumberg D. Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment. Drugs Today (Barc). 2005; 41(12): 773–784.
- Murphy DA, Makonnen S, Lassoued W, et al. Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006). Am J Pathol. 2006; 169(5): 1875–1885.
- König D, Hench J, Frank S, et al. Larotrectinib Response in NTRK3 Fusion-Driven Diffuse High-Grade Glioma. Pharmacology. 2022; 107(7-8): 433–438.
- Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018; 29(8): 1869–1876.
- Ljubimova JY, Sun T, Mashouf L, et al. Covalent nano delivery systems for selective imaging and treatment of brain tumors. Adv Drug Deliv Rev. 2017; 113: 177–200.
- Obara W, Kanehira M, Katagiri T, et al. Present status and future perspective of peptide-based vaccine therapy for urological cancer. Cancer Sci. 2018; 109(3): 550–559.
- Chamani R, Ranji P, Hadji M, et al. Application of E75 peptide vaccine in breast cancer patients: A systematic review and meta-analysis. Eur J Pharmacol. 2018; 831: 87–93.
- Hilf N, Kuttruff-Coqui S, Frenzel K, et al. Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature. 2019; 565(7738): 240–245.
- Schirrmacher V, van Gool S, Stuecker W. Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy. Biomedicines. 2019; 7(3).
- Artusio E, Hathaway B, Stanson J, et al. Transfection of human monocyte-derived dendritic cells with native tumor DNA induces antigen-specific T-cell responses in vitro. Cancer Biol Ther. 2006; 5(12): 1624–1631.
- Anguille S, Van de Velde AL, Smits EL, et al. Immunotherapy in leukaemia. Acta Clin Belg. 2012; 67(6): 399–402.
- Wang B, He J, Liu C, et al. An effective cancer vaccine modality: lentiviral modification of dendritic cells expressing multiple cancer-specific antigens. Vaccine. 2006; 24(17): 3477–3489.
- Van Gool SW, Makalowski J, Feyen O, et al. The induction of immunogenic cell death (ICD) during maintenance chemotherapy and subsequent multimudal immunotherapy for glioblastoma (GBM). Austin Oncol Case Rep. 2018; 3(1): 1010.
- Spitzweg C, Dietz AB, O'Connor MK, et al. In vivo sodium iodide symporter gene therapy of prostate cancer. Gene Ther. 2001; 8(20): 1524–1531.
- Elisei R, Vivaldi A, Ciampi R, et al. Treatment with drugs able to reduce iodine efflux significantly increases the intracellular retention time in thyroid cancer cells stably transfected with sodium iodide symporter complementary deoxyribonucleic acid. J Clin Endocrinol Metab. 2006; 91(6): 2389–2395.
- Mitrofanova E, Unfer R, Vahanian N, et al. Rat sodium iodide symporter for radioiodide therapy of cancer. Clin Cancer Res. 2004; 10(20): 6969–6976.
- Huang M, Batra RK, Kogai T, et al. Ectopic expression of the thyroperoxidase gene augments radioiodide uptake and retention mediated by the sodium iodide symporter in non-small cell lung cancer. Cancer Gene Ther. 2001; 8(8): 612–618.
- Schipper ML, Weber A, Béhé M, et al. Radioiodide treatment after sodium iodide symporter gene transfer is a highly effective therapy in neuroendocrine tumor cells. Cancer Res. 2003; 63(6): 1333–1338.
- Dwyer RM, Bergert ER, O'Connor MK, et al. Sodium iodide symporter-mediated radioiodide imaging and therapy of ovarian tumor xenografts in mice. Gene Ther. 2006; 13(1): 60–66.
- Boland A, Ricard M, Opolon P, et al. Adenovirus-mediated transfer of the thyroid sodium/iodide symporter gene into tumors for a targeted radiotherapy. Cancer Res. 2000; 60(13): 3484–3492.
- Faivre J, Clerc J, Gérolami R, et al. Long-term radioiodine retention and regression of liver cancer after sodium iodide symporter gene transfer in wistar rats. Cancer Res. 2004; 64(21): 8045–8051.
- Wolny M, Syrenicz A. [Sodium iodide symporter in physiology and diseases — the current state of knowledge]. Endokrynol Pol. 2007; 58(6): 512–521.
- Vadysirisack DD, Shen DH, Jhiang SM. Correlation of Na+/I- symporter expression and activity: implications of Na+/I- symporter as an imaging reporter gene. J Nucl Med. 2006; 47(1): 182–190.
- Spitzweg C, Bible KC, Hofbauer LC, et al. Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targets. Lancet Diabetes Endocrinol. 2014; 2(10): 830–842.
- Czarnywojtek A, Warmuz-Stangierska I, Woliński K, et al. Radioiodine therapy in patients with type II amiodarone-induced thyrotoxicosis. Pol Arch Med Wewn. 2014; 124(12): 695–703.
- Czarnywojtek A, Zgorzalewicz-Stachowiak M, Woliński K, et al. Results of preventive radioiodine therapy in euthyroid patients with history of hyperthyroidism prior to administration of amiodarone with permanent atrial fibrillation--a preliminary study. Endokrynol Pol. 2014; 65(4): 269–274.
- Amyes EW, DEEB PH, VOGEL PJ, et al. Determining the site of brain tumors; the use of radioactive iodine and phosphorus. Calif Med. 1955; 82(3): 167–170.
- Mamelak AN, Jacoby DB. Targeted delivery of antitumoral therapy to glioma and other malignancies with synthetic chlorotoxin (TM-601). Expert Opin Drug Deliv. 2007; 4(2): 175–186.
- Vanderpump M. Is lithium an effective adjunct therapy for radioiodine therapy for hyperthyroidism? Clin Endocrinol (Oxf). 2012; 77(4): 513–514.
- Czarnywojtek A, Płazińska MT, Zgorzalewicz-Stachowiak M, et al. Dysfunction of the thyroid gland during amiodarone therapy: a study of 297 cases. Ther Clin Risk Manag. 2016; 12: 505–513.
- Luster M, Pfestroff A, Hänscheid H, et al. Radioiodine Therapy. Semin Nucl Med. 2017; 47(2): 126–134.
- Schirrmacher V. Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance. Expert Opin Biol Ther. 2015; 15(12): 1757–1771.
- Schirrmacher V, Fournier P. Harnessing oncolytic virus-mediated anti-tumor immunity. Front Oncol. 2014; 4: 337.
- Galluzzi L, Vitale I, Warren S, et al. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. J Immunother Cancer. 2020; 8(1).
- Kitzberger C, Spellerberg R, Morath V, et al. The sodium iodide symporter (NIS) as theranostic gene: its emerging role in new imaging modalities and non-viral gene therapy. EJNMMI Res. 2022; 12(1): 25.
- Wapnir IL, van de Rijn M, Nowels K, et al. Immunohistochemical profile of the sodium/iodide symporter in thyroid, breast, and other carcinomas using high density tissue microarrays and conventional sections. J Clin Endocrinol Metab. 2003; 88(4): 1880–1888.
- Spitzweg C, Joba W, Schriever K, et al. Analysis of human sodium iodide symporter immunoreactivity in human exocrine glands. J Clin Endocrinol Metab. 1999; 84(11): 4178–4184.
- Cho JY, Léveillé R, Kao R, et al. Hormonal regulation of radioiodide uptake activity and Na+/I- symporter expression in mammary glands. J Clin Endocrinol Metab. 2000; 85(8): 2936–2943.
- Bruno R, Giannasio P, Ronga G, et al. Sodium iodide symporter expression and radioiodine distribution in extrathyroidal tissues. J Endocrinol Invest. 2004; 27(11): 1010–1014.
- Morgenstern KE, Vadysirisack DD, Zhang Z, et al. Expression of sodium iodide symporter in the lacrimal drainage system: implication for the mechanism underlying nasolacrimal duct obstruction in I(131)-treated patients. Ophthalmic Plast Reconstr Surg. 2005; 21(5): 337–344.
- Tazebay UH, Wapnir IL, Levy O, et al. The mammary gland iodide transporter is expressed during lactation and in breast cancer. Nat Med. 2000; 6(8): 871–878.
- Upadhyay G, Singh R, Agarwal G, et al. Functional expression of sodium iodide symporter (NIS) in human breast cancer tissue. Breast Cancer Res Treat. 2003; 77(2): 157–165.
- Smanik PA, Ryu KY, Theil KS, et al. Expression, exon-intron organization, and chromosome mapping of the human sodium iodide symporter. Endocrinology. 1997; 138(8): 3555–3558.
- Spitzweg C, Scholz IV, Bergert ER, et al. Retinoic acid-induced stimulation of sodium iodide symporter expression and cytotoxicity of radioiodine in prostate cancer cells. Endocrinology. 2003; 144(8): 3423–3432.
